StockData
Abeona Therapeutics Inc. logo

Abeona Therapeutics Inc. (ABEO) stock

ABEONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/3027% below fair value
$2.73+0.13 (+5.00%)

Close on Nov 18, 2026Market cap $156.11MP/E –Yield –

Abeona Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Abeona Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$83.62M. For fiscal 2025 it was -$89.45M. The highest annual figure on record is -$3.13M in fiscal 2014.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$89.45M–
FY2024Dec 31, 2024-$64.21M–
FY2023Dec 31, 2023-$47.14M–
FY2022Dec 31, 2022-$50.92M–
FY2021Dec 31, 2021-$89.84M–
FY2020Dec 31, 2020-$81.42M–
FY2019Dec 31, 2019-$77.09M–
FY2018Dec 31, 2018-$58.17M–
FY2017Dec 31, 2017-$27.84M–
FY2016Dec 31, 2016-$23.88M–
FY2015Dec 31, 2015-$18.55M–
FY2014Dec 31, 2014-$3.13M–
FY2013Dec 31, 2013-$3.80M–
FY2012Dec 31, 2012-$4.32M–
FY2011Dec 31, 2011-$7.88M–
FY2010Dec 31, 2010-$7.76M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$13.65M–
Q1 FY2026Mar 31, 2026-$23.03M–
Q4 FY2025Dec 31, 2025-$22.91M–
Q3 FY2025Sep 30, 2025-$24.02M–
Q2 FY2025Jun 30, 2025-$22.79M–
Q1 FY2025Mar 31, 2025-$19.73M–
Q4 FY2024Dec 31, 2024-$16.67M–
Q3 FY2024Sep 30, 2024-$15.35M–
Q2 FY2024Jun 30, 2024-$17.86M–
Q1 FY2024Mar 31, 2024-$14.33M–
Q4 FY2023Dec 31, 2023-$13.21M–
Q3 FY2023Sep 30, 2023-$11.33M–
Q2 FY2023Jun 30, 2023-$10.55M–
Q1 FY2023Mar 31, 2023-$12.04M–
Q4 FY2022Dec 31, 2022-$12.94M–
Q3 FY2022Sep 30, 2022-$9.38M–
Q2 FY2022Jun 30, 2022-$8.01M–
Q1 FY2022Mar 31, 2022-$20.59M–
Q4 FY2021Dec 31, 2021-$46.65M–
Q3 FY2021Sep 30, 2021-$14.87M–
Q2 FY2021Jun 30, 2021-$13.72M–
Q1 FY2021Mar 31, 2021-$14.60M–
Q4 FY2020Dec 31, 2020-$14.48M–
Q3 FY2020Sep 30, 2020-$6.25M–
Q2 FY2020Jun 30, 2020-$12.48M–
Q1 FY2020Mar 31, 2020-$48.21M–
Q4 FY2019Dec 31, 2019-$16.41M–
Q3 FY2019Sep 30, 2019-$17.65M–
Q2 FY2019Jun 30, 2019-$23.98M–
Q1 FY2019Mar 31, 2019-$19.05M–
Q4 FY2018Dec 31, 2018-$18.01M–
Q3 FY2018Sep 30, 2018-$16.92M–
Q2 FY2018Jun 30, 2018-$12.56M–
Q1 FY2018Mar 31, 2018-$10.68M–
Q4 FY2017Dec 31, 2017-$8.75M–
Q3 FY2017Sep 30, 2017-$5.36M–
Q2 FY2017Jun 30, 2017-$8.44M–
Q1 FY2017Mar 31, 2017-$5.28M–
Q4 FY2016Dec 31, 2016-$5.83M–
Q3 FY2016Sep 30, 2016-$5.17M–

More Abeona Therapeutics figures

See a number that looks wrong?